by the concerted formation of an intramolecular disulfide bond. The corresponding oxidized 48 compound was also characterized as related substance obtained under degradation conditions. 49
The in vitro degradation rate of BUC(NO) 2 was significantly greater than for the other RSNO. 50
For equivalent low and medium • NO-load, BUC(NO) 2 produced a hypotension identical to 51 NACNO, SNAP and the equimolar mixture of SNAP+NACNO, but its effect was greater at 52 higher doses (-62±8 and -47±14 mmHg, maximum ΔMAP for BUC(NO) 2 and 53 SNAP+NACNO, respectively). Its duration of effect on PAP (-50%) lasted from 35 to 95 min, 54
i.e. shorter than for the other RSNO (from 90 to 135 min for the mixture SNAP+NACNO). 55
INTRODUCTION 62
Decrease of nitric oxide ( • NO) bioavailability is associated with cardiovascular 63 diseases such as hypertension, atherosclerosis, angina pectoris [1] . Currently available • SNOPCs induce a more intense decrease of blood pressure than GSNO [14] , even though 81 their in vitro vasodilatory effect was equivalent to GSNO (again at equimolar concentrations 82 of SNO) [12] . These results demonstrate that the molecule carrying the SNO moieties is also a 83 major determinant of the biological activities of RSNO. 84 We previously synthesized a new RSNO, S,S'-dinitrosobucillamine (BUC(NO) 2 , 85 which combines in its structure two mononitrosothiols: S-nitroso-N-acetylpenicillamine 86 (SNAP) and S-nitroso-N-acetylcysteine (NACNO) [11] . The synthesis was performed using 87 bucillamine (BUC(SH) 2 ) which is a commercially available drug used to treat rheumatoid 88 arthritis, in relation with its anti-inflammatory and antioxidant properties [15; 16] . In an aortic 89 ring model, BUC(NO) 2 induced vasorelaxation at lower concentrations (pD 2 7.8 ± 0.1, with 90 pD 2 = -log EC 50 , i.e. the molar concentration producing 50% of the maximal effect) than 91 NACNO (6.4 ± 0.2), SNAP (6.7 ± 0.1) and the mixture of SNAP+NACNO (6.7 ± 0.2). 92 Furthermore, the in vitro • NO release was significantly higher from BUC(NO) 2 (6-fold 93 increase versus basal value) than from the SNAP+NACNO mixture (4-fold increase versus 94 basal value) [11] . Altogether, these data suggest that BUC(NO) 2 might be an interesting 95 5 candidate for the cardiovascular pathologies. However, those previous experiments did not 96 evaluate the systemic effects. 97 Therefore, the present work was conducted to further characterize BUC(NO) 2 . In this 98 aim, we used molecular modeling to study the thermodynamics of the two • NO entities 99 released from BUC(NO) 2 and the resulting bucillamine derived product. We also monitored in 100 vitro the obtained degradation products by using HPLC-MS/MS, and examined in vitro in 101 plasma from Wistar rat spiked with RSNO the rate of decomposition of BUC(NO) 2 as 102 compared to SNAP, NACNO and SNAP+NACNO. Then, we explored the systemic effects 103 and duration of action of BUC(NO) 2 in vivo, using awake male Wistar rats equipped with 104 telemetric devices. On the basis of its • NO-release profile, we assume that BUC(NO) 2 would 105 induce higher and/or longer in vivo hypotensive effects than its constitutive S-mono-106 nitrosothiols SNAP, NACNO. We also compare to an equimolar mixture of NACNO plus 107 SNAP (in order to mimic the quantity of • NO contained in the BUC(NO) 2 solutions). The 108 intensity of hypotension was evaluated on the basis of changes in mean arterial pressure 109 (MAP) which reflect the in vivo dilating effect of RSNO on arteries and arterioles. Changes in 110 pulse arterial pressure (PAP) were used to determine the duration of effect, as we previously 111 showed, using similar protocols, that PAP allows a precise evaluation of RSNO effects 112 duration [17; 18]. 113
MATERIAL and METHODS 114

Reagents and standards 115
All reagents were of analytical grade and used without further purification. N-(2-116 mercapto-2-methylpropanoyl)-L-cysteine (BUC(SH) 2 ) was purchased from Discovery Fine 117 Final solutions showed high osmolarity (1.8 osm/L). The volumes and dilutions 128 required to reach isotonic solutions for injection were too important. Therefore, hyper-129 osmolar solutions were used. Animals received the same volume for each injection (solutions 130 have been diluted according to the expected dose in a final volume of 3.4 mL). In the control 131 (vehicle) solution, nitrite ions were replaced by a 0.2 M NaCl solution. 132
Due to their light-and temperature-sensitivity, final solutions were stored in the dark 133 at 4°C, no longer than 5 days for NACNO and SNAP, and 10 h for BUC(NO) 2 , according to 134 their stability previously described by Dahboul et al. [11] . 135
Theoretical chemistry calculations 136
The computational approach was chosen according to our previous investigations [20] . 137
Specifically, we performed Density Functional Theory calculations (B3PW91 functional [21] 138 with the 6-311+G(d,p) basis-set). In order to account for the influence of the physiological 139 medium, we assumed an ionized system (anionic form of the carboxylic group) surrounded by 140 an aqueous environment (described by an implicit solvation model [22] ). A thorough analysis 141 of BUC(NO) 2 conformations was first performed. In the most stable structure, the peptide 142 bond is (as expected) in trans conformation and both RS-NO bonds adopt an anti 143 conformation. From this structure, we calculated the sequential homolytic bond dissociation 144 free energies (at 298.15 K) for the two RS-NO bonds. The two possible monoradical and the 145 biradical species were studied. Besides, we considered a hypothetical mechanism for the 146 second • NO dissociation in which the formation of an incipient disulfide bond significantly 147 stabilizes the process. All computations were carried out using the Gaussian09 package [23]. 148
Identification of degradation product(s) from S,S'-dinitrosobucillamine 149
In order to check the reliability of the theoretical predictions, we have carried out LC-150 MS/MS experiments aimed at identifying the molecular structure of a main degradation 151 product obtained after exposure of BUC(NO) 2 to either heating (55°C, 120 min) or H 2 O 2 152 (10.0% v/v, 15 min). Such conditions have been previously used in the field of toxicology 153 predictions [24] . 154
The stock BUC(NO) 2 solution (10 -2 M in phosphate buffer pH 7.4) with and without 155 H 2 O 2 was diluted one thousand times in the mobile phase before injection in the LC system. MS analysis was carried out in negative ionization mode using an ion spray voltage of -164 4500V. The curtain gas flow was set at 25 psi using nitrogen. The turbo VTM ion source was 165 set at 550°C. Nebulizer gas and auxiliary gas flow (air) were set at 50 psi. Acquisition was 166 performed in IDA "Information Dependent Acquisition" method. The IDA method consists of 167 a switch between MS (survey scan) and MS/MS (dependent scan) in a single run. 168
In vitro measurement of S,S'-dinitrosobucillamine degradation in spiked plasma 169
In order to confirm our in silico and in vitro findings, we compared the rate of The second dissociation process is much faster than the first one because of the 252 concerted formation of a disulfide bond, which substantially stabilizes the system. 253 Accordingly, the second dissociation proceeds through a transition structure that leads to a 254 disulfide product ( Figure 1) and it is only 9.1 kcal.mol -1 above the monoradical species in path 255 P 1 (or 12.3 kcal.mol -1 in P 2 ). As a consequence of this low activation free energy for the 256 second dissociation process, in BUC(NO) 2 the first dissociation step can be considered the 257 rate determining for the double dissociation. 
Identification of the main degradation product of S,S'-dinitrosobucillamine 270
The degradation processes, monitored by mass-coupled liquid chromatography, led to 271 similar results for both stress conditions. A chromatogram of a fresh BUC(NO) 2 solution is 272 illustrated on Figure 2A with its MS/MS spectrum in Figure 2B showing a specific molecular 273 ion at m/z 280. All the molecular structures determined in this part are described in Table 1 . Degradation conditions presently used led to the appearance of a chromatographic 282 peak at a retention time of 6.8 min. (Figure 2C and 2E for oxidation and heating, 283 respectively). The MS/MS spectra of this degradation product are given in Figure 2D and 2F 284 with a m/z major ion at 220 amu corresponding to the [BUC(S-S)-H]structure. It is important 285 to note that no other molecular ions were detected at m/z values upper than m/z 300, leading 286 to the conclusion that the disulfide bond formation is only favored through an intramolecular 287 pathway. Furthermore, the mononitrosated bucillamine was not observed whatever the 288 chromatogram under study, indicating that the denitrosation process is rapid and 289 simultaneously concerns the two thiol groups included in the BUC(NO) 2 structure. 290
3.3.Kinetics for RSNO decomposition in plasma 291
We added RSNO to plasma in vitro, to evaluate their decomposition rate. As shown in 292 The increases in MAP were masked when rats received RSNO, except for the lowest 311 dose of BUC(NO) 2 (Figures 4 to 6) . Each drug induced a dose-dependent hypotension (fall in 312 MAP). When comparing the maximal hypotension produced by the different treatments, at 313 doses that are expected to release similar amounts of • NO, there was no significant difference 314 between BUC(NO) 2 and the SNAP+NACNO mixture at 3.5 and 7 µmol/kg, but a trend for a 315 greater hypotension with BUC(NO) 2 compared to SNAP+NACNO at 14 µmol/kg (Table 2) . 316
The changes in MAP lasted from 5 (lowest doses) to 50 min (highest doses) with no 317 significant differences amongst the treatments (p interaction = 0.0680; p drug = 0.2418; p dose < 10 -4 ; 318 data not shown). 319
These changes in MAP induced significant increases in HR (stimulation of the 320 baroreflex) when compared to vehicle-treated animals (Figure 7) . No noticeable difference 321 14 could be observed among the groups receiving RSNO. The duration of the changes in HR did 322 not differ amongst treatments, except for BUC(NO) 2 which induced a shorter effect than the 323 SNAP+NACNO mixture (Figure 8) . 324
The duration of falls in PAP (around -15 mmHg for all drugs, whatever the doses used, 325 This parallels the in vitro results obtained in previous studies realized on isolated aortic rings, 396 in which BUC(NO) 2 induced relaxation for the smallest concentration ( In the present study, changes in PAP were used to evaluate the duration of the RSNO effects. 408 PAP is a function of arterial compliance/elastance, cardiac output and arterial tone, neither of 409 which were measured in the present study as the protocols would have been too stressful for 410 the animals. However, we used the duration of effect on PAP as a measure of the duration of 411 the effect of RSNO, as (i) we previously published similar approach in [17; 18] and (ii) RSNO 412 are known to induce large venodilation [26] . Venodilation decreases venous return and 413 cardiac preload and thus decreases stroke volume, the main factor controlling PAP. Therefore, 414 PAP would decrease. We previously showed by direct measurements of aortic pulse wave 415 velocity [27] that • NO-donor administration did not change the second factor controlling PAP, 416
i.e. aortic wall elasticity. We thus suggest that the fall in PAP is most likely related to a fall in 417 stroke volume consecutive to venodilation. However, we cannot rule out that other factors are 418 in fractionated blood (plasma vs. blood cells) using gas-phase chemiluminescence reaction 431 with ozone and the total nitrate and nitrite species (NO x ) using a Griess colorimetric-based 432 method. Despite marked differences in hemodynamic effects, they failed to see any difference 433 in the pharmacokinetic profiles of these drugs, suggesting that blood monitoring of total 434 RSNO and NOx might not be sensitive enough to enable the determination of the 435 pharmacokinetic profiles of RSNO. 436 In order to assess the metabolism of BUC(NO) 2 , we used an in vitro approach 437 consisting in loading freshly prepared plasma with RSNO. In this biological environment, we 438 observed a significant faster degradation of BUC(NO) 2 compared with the other RSNO. Even 439 though this approach cannot be considered as a pharmacokinetic study, these results are 440 consistent with our in silico and in vivo results and seem to confirm a faster metabolism for 441 BUC(NO) 2 . 442
Assuming a 100% • NO release, we compared, with respect to the molar concentrations 443 of • NO, the effects of the dinitrosothiol BUC(NO) 2 and the SNAP+NACNO mixture, 444 mononitrosothiols and other • NO-donors, i.e. isosorbide dinitrate (ISDN) and sodium 445 nitroprusside (SNP) ( Table 4 ). For a similar • NO-load, BUC(NO) 2 induces the shortest effects. 446
The duration of its effects is half of the value obtained with SNAP+NACNO mixture and it is 447 no longer than that of mononitrosothiols such as GSNO (Table 4 and [17; 18]). When ISDN 448 was injected subcutaneously, it did not induce any significant hypotension but a 15 mmHg 449 decrease in PAP which lasted 37 min even at very high doses. Concerning SNP, the efficient 450 dose to induce hypotension was 0.35 µmol/kg (0.0035 and 0.035 µmol/kg had no effect), with 451 a -17 mmHg decrease in PAP lasting almost 100 min. At the dose of 3.5 µmol/kg, 2 out of the 452 5 rats died while the remaining ones underwent severe and prolonged hypotension (which led 453 us to sacrifice the rats for exceeding the ethical limit points). These data led to several 454 assumptions. 455 First, all RSNO produce in vivo both arterial (effect on MAP) and venous (effect on 461 PAP) dilations. Despite the lack of report on PAP data, this can be assumed even for 462 SNOPCs, with regards to the raw blood pressure recordings provided by Heikal et al. [14] . 463 This is also the case for SNP but not for ISDN, which only produces a decrease in PAP, 464 reflecting venodilation. 465 Second, regarding the arterial effect, RSNO seem less efficient than SNP, as they 466 require a 20 to 40-fold higher • NO-load to produce similar hypotension. However, they appear 467 safer, with a larger margin of safety, as they do not release cyanate leading to toxicity and 468 death as observed at the end of this study (injection of SNP). The protocol used by Heikal et 469 al. did not allow us to compare the arterial effect of SNOPCs to that of the drugs used in the 470 present report as 1) the different routes of administration used (subcutaneous vs. intravenous) 471 obviously imply a different dose range and 2) hemodynamics were not recorded in the same 472 conditions (awake rats vs. anesthetized mice). 473
